Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy

NCT01233947 is registered in ClinicalTrials.gov with Tigris Pharmaceuticals as lead sponsor.

NCT NCT01233947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01233947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy
Lead sponsor
Tigris Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2011
Completion date
August 31, 2012
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm